BioLife Solutions (BLFS) said Monday it has acquired $2 million of convertible notes in biotechnology company Pluristyx as part of a larger financing round.
BioLife also said it signed a separate agreement with Pluristyx that gives it a board observer seat and provides it with certain rights relating to a potential future acquisition of Pluristyx.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.